Aspirin Mouthwash in Treating Patients With Oral Leukoplakia

Precancerous Condition Clinical Trial

Official title:

Oral Topical Cyclooxygenase Inhibitor (Aspirin) Mouthwash for Treatment of Oral Dysplasia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01238185
• Other study ID #: INHANSE-ASPOD
• Secondary ID: CDR0000688122ISR
• Status: Completed
• Phase: Phase 1
• First received: November 9, 2010
• Last updated: August 9, 2013
• Start date: February 2010
• Est. completion date: October 2011

Study information

• Verified date: November 2010
• Source: National Cancer Institute (NCI)
• Contact: n/a
• Is FDA regulated: No
• Health authority: Unspecified
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Aspirin mouthwash may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

PURPOSE: This phase I trial is studying the side effects and best dose of aspirin mouthwash in treating patients with oral leukoplakia.

Description:

OBJECTIVES:

• To determine if oral topical acetylsalicylic acid mouthwash achieves modulation of COX-1, COX-2, and prostaglandin in oral dysplasia tissues in patients with oral leukoplakia.

• To determine if this drug achieves alteration of histopathology and gene and protein expression in tissue.

• To determine if this drug achieves aspirin-induced tissue changes relating to altered tumor biology.

• To assess local and general tolerability and safety of this drug in these patients.

OUTLINE: All patients undergo tissue biopsy for histological diagnosis. Patients without a histological diagnosis of precancerous oral dysplasia undergo routine follow-up. Patients with a histological diagnosis of precancerous oral dysplasia are sequentially allocated to 1 of 4 treatment groups.

• Group 1: Patients receive acetylsalicylic acid mouthwash (one 75 mg tablet dissolved in 250 mL of water) twice daily for 4-6 weeks, gargling for 60 seconds then expectorate it fully, before planned definitive surgical excision.

• Group 2: Patients receive acetylsalicylic acid mouthwash (two 75 mg tablets of acetylsalicylic acid dissolved in 250 mL of water) twice daily for 4-6 weeks, gargling for 60 seconds then expectorate it fully, before planned definitive surgical excision.

• Group 3: Patients receive acetylsalicylic acid mouthwash (one 300 mg tablet of acetylsalicylic acid dissolved in 250 mL of water) twice daily for 4-6 weeks, gargling for 60 seconds then expectorate it fully, before planned definitive surgical excision.

• Group 4: Patients receive acetylsalicylic acid mouthwash (one 300 mg tablet of acetylsalicylic acid dissolved in 250 mL of water) three times daily for 4-6 weeks, gargling for 60 seconds then expectorate it fully, before planned definitive surgical excision.

At the time of definitive surgical excision, the patient is asked to gargle with the last dose of acetylsalicylic acid mouthwash just before being anesthetized. A small biopsy of the dysplasia lesion is taken and examined for immediate effects of the acetylsalicylic acid mouthwash on the dysplasia lesion. The surgically excised tissue is treated in the same way as the initial biopsy tissue (i.e., half being used for routine histology to confirm the diagnosis and the other half for research purposes). Tissue samples are analyzed via enzyme immunosorbent assay, qRT-PCR, immunoblotting, ELISA, immunohistochemistry, gene array analysis, and microvessel density analysis.

Patients complete a questionnaire assessing local and general tolerability as well as adverse effects during the period of use of the mouthwash.

After completion of study treatment, patients are followed periodically.

Peer Reviewed and Funded or Endorsed by Cancer Research UK

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: October 2011
• Est. primary completion date: October 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A and older

Eligibility

DISEASE CHARACTERISTICS:

• Clinically diagnosed oral leukoplakia requiring a tissue biopsy for histological diagnosis

• Attending the outpatient clinic

PATIENT CHARACTERISTICS:

• Not nursing

• No known or suspected sensitivity to aspirin or other nonsteroidal anti-inflammatory drugs

• No diagnosis of asthma or angioedema

• No contraindications, including any of the following:

• Active peptic ulceration or a history of peptic ulceration

• Hemophilia or a history of bleeding disorders

• Gout or a history of gout

PRIOR CONCURRENT THERAPY:

• No concurrent regular use of aspirin for heart disease or other reasons

• No other concurrent nonsteroidal anti-inflammatory drugs

Study Design

Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Precancerous Condition
• Precancerous Conditions

Intervention

Drug:
• acetylsalicylic acid

Genetic:
• gene expression analysis

• protein expression analysis

Other:
• laboratory biomarker analysis

• questionnaire administration

Procedure:
• biopsy

Locations

Country	Name	City	State
United Kingdom	University of Birmingham	Birmingham	England
United Kingdom	Institute of Head and Neck Studies and Education	Coventry	England

Sponsors (1)

Lead Sponsor	Collaborator
Institute of Head and Neck Studies and Education, United Kingdom

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	PGE2 levels as assessed by enzyme immunosorbent assay			No
Primary	COX-1 and COX-2 mRNA as assessed by qRT-PCR			No
Primary	COX-1 and COX-2 protein expression as assessed by immunohistochemistry and quantified by immunoblotting to determine whether COX inhibition in oral dysplasia tissues is actually possible by use of the mouthwash formulation			No
Secondary	Comparison of WHO histological grade and clinical size of dysplastic lesions before and after treatment and assessment of proliferating cell nuclear antigen			No
Secondary	Tolerability and possible oral and other adverse effects using a questionnaire			Yes
Secondary	VEGF mRNA expression as assessed by qRT-PCR			No
Secondary	Protein expression as assessed by ELISA and immunohistochemistry for VEGFA			No
Secondary	Global gene response of dysplastic tissue as assessed by Affymetrix gene expression microarrays			No